Juan C. Jaen - 09 Jul 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Reporting relationship: President
Issuer ticker: RCUS
Reported as of: 09 Jul 2026
Net transaction value: -$2,031,919
SEC form: 4
Accepted by SEC: 13 Jul 2026, 17:36:46 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Tang, Attorney-in-Fact

Key filing fact

Juan C. Jaen filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 13 Jul 2026.

Key facts

This page summarizes Juan C. Jaen's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 17:36.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: -$2,031,919.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001422996 Primary reporting owner

Jaen Juan C.

Relationship: President
Address: C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCUS transaction

Common Stock

Sale

Transaction value: $1,457,631
Shares: -48,502
Change %: -5.4%
Price: $30.05
Shares after: 842,307
Date: 09 Jul 2026
Ownership: By Trust
Footnotes: F1, F2

RCUS transaction

Common Stock

Sale

Transaction value: $566,410
Shares: -19,799
Change %: -2.4%
Price: $28.61
Shares after: 822,508
Date: 10 Jul 2026
Ownership: By Trust
Footnotes: F1, F3

RCUS transaction

Common Stock

Sale

Transaction value: $7,878
Shares: -268
Change %: -0.03%
Price: $29.40
Shares after: 822,240
Date: 10 Jul 2026
Ownership: By Trust
Footnotes: F1, F4

RCUS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 378,291
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F3

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F4

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F5

Includes the unvested portion of the Reporting Person's RSU grants.